Steritas' John Stone analyses the benefits that a quantifiable index system can have for researchers looking into steroid toxicity, and how this can allow them to work with larger sets of patient ...
The Journal for Clinical Studies (JCS) sat down with John Stone, MD MPH, Chair of the Steritas Scientific Board, to discuss the steroid-toxicity epidemic. Read the full interview, which begins on ...
Megan Thomas of Drug Discovery World (DDW) spoke with Martha Stone, CEO of Steritas, and other industry experts about their predictions for drug discovery opportunities in 2025. Read the article here.
First-in-class steroid-toxicity outcome assessments licensed by argenx to support the development of novel steroid-sparing therapeutics for autoimmune diseases Boston, MA, USA, 19 November 2024: ...
Study will allow researchers to assess the outcomes of intravenous and oral glucocorticoid protocols in children Boston, MA, USA, 24 September 2024: Steritas LLC., a company dedicated to enhancing ...
Steritas is very pleased to have been named Startup of the Year during the 2023 SAMPS Awards. The annual SAMPS awards celebrate companies that are doing important work in the life science and applied ...